<VariationArchive VariationID="632418" VariationName="NM_033629.6(TREX1):c.635del (p.Pro212fs)" VariationType="Deletion" Accession="VCV000632418" Version="5" RecordType="classified" NumberOfSubmissions="2" NumberOfSubmitters="2" DateLastUpdated="2024-05-12" DateCreated="2019-05-27" MostRecentSubmission="2024-02-28">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="620127" VariationID="632418">
      <GeneList>
        <Gene Symbol="ATRIP" FullName="ATR interacting protein" GeneID="84126" HGNC_ID="HGNC:33499" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>3p21.31</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="48446737" stop="48467645" display_start="48446737" display_stop="48467645" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="48488113" stop="48507053" display_start="48488113" display_stop="48507053" Strand="+" />
          </Location>
          <OMIM>606605</OMIM>
        </Gene>
        <Gene Symbol="ATRIP-TREX1" FullName="ATRIP-TREX1 readthrough" GeneID="111822955" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>3p21.31</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="48446779" stop="48467645" display_start="48446779" display_stop="48467645" Strand="+" />
          </Location>
        </Gene>
        <Gene Symbol="TREX1" FullName="three prime repair exonuclease 1" GeneID="11277" HGNC_ID="HGNC:12269" Source="submitted" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>3p21.31</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="48465830" stop="48467645" display_start="48465830" display_stop="48467645" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="48506918" stop="48509043" display_start="48506918" display_stop="48509043" Strand="+" />
          </Location>
          <OMIM>606609</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_033629.6(TREX1):c.635del (p.Pro212fs)</Name>
      <CanonicalSPDI>NC_000003.12:48467288:CC:C</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>3p21.31</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="48467289" stop="48467289" display_start="48467289" display_stop="48467289" variantLength="1" positionVCF="48467288" referenceAlleleVCF="AC" alternateAlleleVCF="A" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="48508688" stop="48508688" display_start="48508688" display_stop="48508688" variantLength="1" positionVCF="48508687" referenceAlleleVCF="AC" alternateAlleleVCF="A" />
      </Location>
      <ProteinChange>P202fs</ProteinChange>
      <ProteinChange>P212fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000003.11" sequenceAccession="NC_000003" sequenceVersion="11" change="g.48508689del" Assembly="GRCh37">
            <Expression>NC_000003.11:g.48508689del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000003.12" sequenceAccession="NC_000003" sequenceVersion="12" change="g.48467290del" Assembly="GRCh38">
            <Expression>NC_000003.12:g.48467290del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009820.2" sequenceAccession="NG_009820" sequenceVersion="2" change="g.6461del">
            <Expression>NG_009820.2:g.6461del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_033100.1" sequenceAccession="NG_033100" sequenceVersion="1" change="g.38572del">
            <Expression>NG_033100.1:g.38572del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_041782.1" sequenceAccession="NG_041782" sequenceVersion="1" change="g.25581del">
            <Expression>NG_041782.1:g.25581del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="non-coding">
          <NucleotideExpression sequenceAccessionVersion="NR_153405.1" sequenceAccession="NR_153405" sequenceVersion="1" change="n.3944del">
            <Expression>NR_153405.1:n.3944del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001619" Type="non-coding transcript variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_007248.5" sequenceAccession="NM_007248" sequenceVersion="5" change="c.605del">
            <Expression>NM_007248.5:c.605del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_009179.2" sequenceAccession="NP_009179" sequenceVersion="2" change="p.Pro202fs">
            <Expression>NP_009179.2:p.Pro202fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_033629.6" sequenceAccession="NM_033629" sequenceVersion="6" change="c.635del" MANESelect="true">
            <Expression>NM_033629.6:c.635del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_338599.1" sequenceAccession="NP_338599" sequenceVersion="1" change="p.Pro212fs">
            <Expression>NP_338599.1:p.Pro212fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001271023.2" sequenceAccession="NM_001271023" sequenceVersion="2" change="c.*1736del">
            <Expression>NM_001271023.2:c.*1736del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001624" Type="3 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_032166.4" sequenceAccession="NM_032166" sequenceVersion="4" change="c.*1736del">
            <Expression>NM_032166.4:c.*1736del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001624" Type="3 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_130384.3" sequenceAccession="NM_130384" sequenceVersion="3" change="c.*1736del" MANESelect="true">
            <Expression>NM_130384.3:c.*1736del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001624" Type="3 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_282" sequenceAccession="LRG_282">
            <Expression>LRG_282:g.6461del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_282t1" sequenceAccession="LRG_282t1">
            <Expression>LRG_282t1:c.635del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_282p1" sequenceAccession="LRG_282p1" change="p.Pro212fs">
            <Expression>LRG_282p1:p.Pro212fs</Expression>
          </ProteinExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="756664985" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_033629.6(TREX1):c.635del (p.Pro212fs) AND TREX1-related disorder" Accession="RCV000779412" Version="4">
        <ClassifiedConditionList TraitSetID="33696">
          <ClassifiedCondition DB="MedGen" ID="CN239414">TREX1-related disorder</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2018-11-22" SubmissionCount="1">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_033629.6(TREX1):c.635del (p.Pro212fs) AND multiple conditions" Accession="RCV003768447" Version="1">
        <ClassifiedConditionList TraitSetID="12753">
          <ClassifiedCondition DB="MedGen" ID="C0796126">Aicardi-Goutieres syndrome 1</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0024145">Chilblain lupus 1</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1860518">Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-10-10" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-10-10" NumberOfSubmissions="2" NumberOfSubmitters="2" DateCreated="2019-05-27" MostRecentSubmission="2024-02-28">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic/Likely pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">17660818</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20131292</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24183309</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">27943079</ID>
        </Citation>
        <DescriptionHistory Dated="2024-02-25">
          <Description>Likely pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="12753" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="141" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Aicardi-Goutieres syndrome 1</ElementValue>
                <XRef ID="MONDO:0009165" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">CREE ENCEPHALITIS</ElementValue>
                <XRef Type="MIM" ID="225750" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">ENCEPHALOPATHY, FAMILIAL INFANTILE, WITH INTRACRANIAL CALCIFICATION AND CHRONIC CEREBROSPINAL FLUID LYMPHOCYTOSIS</ElementValue>
                <XRef Type="MIM" ID="225750" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">PSEUDOTOXOPLASMOSIS SYNDROME</ElementValue>
                <XRef Type="MIM" ID="225750" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">AGS1</ElementValue>
                <XRef Type="MIM" ID="225750" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">AGS</ElementValue>
                <XRef Type="MIM" ID="225750" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15167" />
                <XRef ID="15167" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10893" />
                <XRef ID="10893" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Most characteristically, Aicardi-Goutières syndrome (AGS) manifests as an early-onset encephalopathy that usually, but not always, results in severe intellectual and physical disability. A subgroup of infants with AGS present at birth with abnormal neurologic findings, hepatosplenomegaly, elevated liver enzymes, and thrombocytopenia, a picture highly suggestive of congenital infection. Otherwise, most affected infants present at variable times after the first few weeks of life, frequently after a period of apparently normal development. Typically, they demonstrate the subacute onset of a severe encephalopathy characterized by extreme irritability, intermittent sterile pyrexias, loss of skills, and slowing of head growth. Over time, as many as 40% develop chilblain skin lesions on the fingers, toes, and ears. It is becoming apparent that atypical, sometimes milder, cases of AGS exist, and thus the true extent of the phenotype associated with pathogenic variants in the AGS-related genes is not yet known.</Attribute>
                <XRef ID="NBK1475" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301648</ID>
                <ID Source="BookShelf">NBK1475</ID>
              </Citation>
              <XRef ID="51" DB="Orphanet" />
              <XRef ID="C0796126" DB="MedGen" />
              <XRef ID="MONDO:0009165" DB="MONDO" />
              <XRef Type="MIM" ID="225750" DB="OMIM" />
            </Trait>
            <Trait ID="6104" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Vasculopathy, retinal, with cerebral leukodystrophy</ElementValue>
                <XRef ID="Vasculopathy%2C+retinal%2C+with+cerebral+leukodystrophy/7360" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cerebroretinal vasculopathy, hereditary</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Retinopathy, vascular, with cerebral and renal involvement and Raynaud and migraine phenomena</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations</ElementValue>
                <XRef ID="MONDO:0008641" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">CRV</ElementValue>
                <XRef Type="MIM" ID="192315" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">RVCL</ElementValue>
                <XRef ID="GTR000553865" DB="Genetic Testing Registry (GTR)" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">RVCLS</ElementValue>
                <XRef Type="MIM" ID="192315" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">TREX1-Related Retinal Vasculopathy with Cerebral Leukoencephalopathy and Systemic Manifestations</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S) is a small-vessel disease that affects highly vascularized tissues including the retina, brain, liver, and kidneys. Age of onset is often between 35 and 50 years. The most common presenting finding is decreased visual acuity and/or visual field defects. Neurologic manifestations may include hemiparesis, facial weakness, aphasia, and hemianopsia. Migraines and seizures are less frequently described. Renal manifestations may include mild-to-moderate increase in serum creatinine and mild proteinuria; progression to end-stage renal disease (ESRD) is uncommon. Hepatic manifestations frequently include mildly elevated levels of alkaline phosphatase and gamma-glutamyltransferase (GGT). Less common findings include psychiatric disorders, hypertension, mild-to-moderate anemia, and Raynaud phenomenon.</Attribute>
                <XRef ID="NBK546576" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="1217" />
                <XRef ID="1217" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">31536185</ID>
                <ID Source="BookShelf">NBK546576</ID>
              </Citation>
              <XRef ID="247691" DB="Orphanet" />
              <XRef ID="3421" DB="Orphanet" />
              <XRef ID="63261" DB="Orphanet" />
              <XRef ID="71291" DB="Orphanet" />
              <XRef ID="C1860518" DB="MedGen" />
              <XRef ID="MONDO:0008641" DB="MONDO" />
              <XRef Type="MIM" ID="192315" DB="OMIM" />
            </Trait>
            <Trait ID="1425" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Chilblain lupus 1</ElementValue>
                <XRef ID="MONDO:0012500" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">CHBL1</ElementValue>
                <XRef Type="MIM" ID="610448" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="18493" />
                <XRef ID="18493" DB="Office of Rare Diseases" />
              </AttributeSet>
              <XRef ID="C0024145" DB="MedGen" />
              <XRef ID="MONDO:0012500" DB="MONDO" />
              <XRef Type="MIM" ID="610448" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="33696" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="36611" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">TREX1-related condition</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">TREX1-related disorder</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">TREX1-Related Disorders</ElementValue>
              </Name>
              <XRef ID="CN239414" DB="MedGen" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1791102" SubmissionDate="2019-02-01" DateLastUpdated="2019-05-27" DateCreated="2019-05-27">
        <ClinVarSubmissionID localKey="665047" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000916025" DateUpdated="2019-05-27" DateCreated="2019-05-27" Type="SCV" Version="1" SubmitterName="Illumina Laboratory Services, Illumina" OrgID="504895" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-11-22">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">24183309</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">17660818</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20131292</ID>
          </Citation>
          <Comment>The TREX1 c.635delC (p.Pro212HisfsTer65) variant results in a frameshift and is predicted to result in premature termination of the protein. This variant is located in the last exon of the gene and may escape nonsense-mediated decay. The p.Pro212HisfsTer65 variant has been reported in three studies in which it is found in a total of three individuals including two with a diagnosis of Aicardi-Goutieres syndrome (Ramantani et al. 2010; Rice et al. 2013) and one individual with systemic lupus erythematosus (Lee-Kirsch et al. 2007). One of the subjects with Aicardi-Goutieres was homozygous for the p.Pro212HisfsTer65 variant and the second was compound heterozygous for the variant and a missense variant. The p.Pro212HisfsTer65 variant has not been reported in the literature in association with retinal vasculopathy with cerebral leukodystrophy. The variant was absent from 1612 healthy control subjects and is reported at a frequency of 0.000015 in the European (non-Finnish) population from the Exome Aggregation Consortium but this is based on one allele, in a region of good sequencing coverage, so the variant is presumed to be rare. Functional studies showed that, when overexpressed in HeLa cells, GFP tagged TREX1 p.Pro212HisfsTer65, , alters the subcellular distribution of TREX1 and might therefore interfere with its function (Lee-Kirsch et al. 2007). Based on the collective evidence the p.Pro212HisfsTer65 variant is classified as likely pathogenic for TREX-related disorders. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ICSL Variant Classification Criteria 09 May 2019</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/thsgk7t4/icsl_variant_classification_criteria_09_may_2019.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="TREX1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="3" alternateAllele="A" referenceAllele="AC" start="48508687" stop="48508688" variantLength="2" />
          </Location>
          <AttributeSet>
            <Attribute Type="HGVS">NM_033629.3:c.635delC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">TREX1-Related Disorders</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="CN239414" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB5118208</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="8525635" SubmissionDate="2024-02-15" DateLastUpdated="2024-02-28" DateCreated="2024-02-28">
        <ClinVarSubmissionID localKey="4843305|MedGen:C1860518;C0796126;C0024145" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004569653" DateUpdated="2024-02-28" DateCreated="2024-02-28" Type="SCV" Version="1" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-10-10">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">20131292</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27943079</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">17660818</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Pro212Hisfs*65) in the TREX1 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 103 amino acid(s) of the TREX1 protein. This variant is present in population databases (rs756664985, gnomAD 0.0009%). This premature translational stop signal has been observed in individuals with Aicardi-Goutieres syndrome (PMID: 20131292, 27943079). This variant is also known as P212fsX276. ClinVar contains an entry for this variant (Variation ID: 632418). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this premature translational stop signal affects TREX1 function (PMID: 17660818). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="TREX1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000003.11:g.48508688del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease" multipleConditionExplanation="Uncertain">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1860518" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0796126" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0024145" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14224806</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="8525635" TraitType="Disease" MappingType="XRef" MappingValue="C0796126" MappingRef="MedGen">
        <MedGen CUI="C0796126" Name="Aicardi-Goutieres syndrome 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="8525635" TraitType="Disease" MappingType="XRef" MappingValue="C0024145" MappingRef="MedGen">
        <MedGen CUI="C0024145" Name="Chilblain lupus 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="8525635" TraitType="Disease" MappingType="XRef" MappingValue="C1860518" MappingRef="MedGen">
        <MedGen CUI="C1860518" Name="Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1791102" TraitType="Disease" MappingType="Name" MappingValue="TREX1-Related Disorders" MappingRef="Preferred">
        <MedGen CUI="CN239414" Name="TREX1-related disorder" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

